IL13 and asthma: Anti-IL13 mAbs (tralokinumab and lebrikizumab) reduce TARC levels, but TARC data was not reported in the LAVOLTA I, LAVOLTA II, STRATOS1, or STRATOS2 trials, so there is minimal clinical data regarding anti-IL13 therapy and TARC biomarker utility for asthma [59,60,103].